The US food and drug administration said that on Friday it has ratified the use of additional batches from a one-dose vaccine Johnson & Johnson produced at the Baltimore factory that was worried not put in a bottle – can make up to 15 million doses of J & J vaccine, according to sources who are familiar with this problem.
The FDA has now authorized a total of four vaccine batches produced at the facility that appear.
“While the FDA is not ready to enter the biosolutions factory that appears …
as an official manufacturing facility, the agency continues to work through problems there with biossen and general management,” said agency in a statement, referring to the pharmacy J & J unit.
The production of J & J vaccine on the Baltimore website was stopped by the US authorities in April after the discovery that the ingredients of the Covid-19 vaccine astrazeneca, were also produced at the factory at the time, polluting batch vaccines J & J.
FDA inspection plants also appeared Long sanitation problems and poor manufacturing practices.
“When Covid-19 continues to affect the countries and cause countless to suffer throughout the world, we remain committed to producing safe and high-quality vaccines,” J & J said in a statement.
J & J shares closed around 2% at $ 168.98.